Table 2.

Role of natural killer T cells in mouse models of systemic lupus erythematosus.

Strain (Model), Age	Treatment	Outcomes	Ref.
NZB/NZW F1 (BWF1) mice	None	Expansion of NKT cells in association with the onset of the disease	[30]
MRL/lpr mice, 2 months of age	6 μg of alpha-galactosylceramide (α-GalCer) twice a week for 5 months	Improvement in inflammatory dermatitis without affecting renal disease	[34]
BALB/c and SJL mice (pristane-induced)	6 μg of α-GalCer twice a week for 1 month	Suppression of nephritis (BALB/c mice): exacerbation of nephritis (SJL mice)	[35]
BWF1 young mice	0.5 mg of anti-NK1.1 antibody three times a week for long periods	Amelioration of nephritis in late disease phase (worsening in early phase)	[37]
BWF1 mice, 20 weeks of age	4 μg of α-GalCer twice a week for 2 weeks	Enhancement of Th1 immune responses and exacerbation of nephritis	[38]
BWF1 mice, 7 weeks of age	4 μg of α-GalCer twice at a 3-day interval	Suppression of IL-10 production and reduction of severe proteinuria	[39]
BWF1 mice, 24 weeks of age	2 μg of α-GalCer once a week for 4 weeks	Suppression of Th2 immune responses and amelioration of nephritis	[41]